philip borden.jpeg

Mr. Borden is a Managing Director of Galen Partners and has nearly 20 years of healthcare investing experience.  He has played a leadership role in building several market-leading companies, including Quantum Medical Imaging, IPA, BioAgilytix, IZI Medical, Dominion Diagnostics, Pilgrim Quality Solutions, Allied Dental and Tegra Medical.  Over his career, he has made investments in medical products and equipment, healthcare services, healthcare IT, outsourced manufacturing, diagnostics and laboratories, and analytical instrumentation.

Prior to joining Galen, Mr. Borden was a General Partner at Riverside Partners, a middle-market private equity firm focused on healthcare and technology investments.  During his 10+ year tenure at Riverside, Mr. Borden built and spearheaded much of the firm’s activity in the healthcare industry.

Mr. Borden began his investment career at Frazier Healthcare in Seattle, working on both healthcare growth equity and buyout transactions.

Mr. Borden is currently President of the Board for MitoAction, a non-profit that provides advocacy, education, and support for patients and families with mitochondrial disease.

Mr. Borden holds a Bachelor of Science degree in Cell and Molecular Biology from Duke University, with honors, and a Master in Business Administration from Harvard Business School, where he graduated with highest distinction as a Baker Scholar.